Ana Mariño

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero et al. · The Lancet Infectious Diseases · 2015 · 130 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Neurovirology +9

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C

Luz Martı́n-Carbonero, Marina Núñez, Ana Mariño et al. · AIDS · 2008 · 64 citations

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero et al. · Journal of Antimicrobial Chemotherapy · 2016 · 62 citations · Full text

Contribution of Immunological and Virological Factors to Extremely Severe Primary HIV Type 1 Infection

Judith Dalmau, María C. Puertas, Marta Azuara et al. · Clinical Infectious Diseases · 2008 · 46 citations · Full text

Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa®), in antiretroviral-naïve patients: A 48-week, multicentre, randomized study (Lake Study)

Patricia Echeverría, Eugènia Negredo, Giampiero Carosi et al. · Antiviral Research · 2009 · 30 citations

Antiretroviral-naïve Patients, Similar Antiviral Efficacy, Antiviral Drug Development +6